HOT Screen GmbH

Contract Research Organisation Specialising in Active Substance Characterisation for the Pharmaceutical, Food Supplement, Cosmetics and Medical Device Sectors

HOT Screen GmbH is an innovative contract research and development company specialising in the characterisation of active substances for the pharmaceutical, food supplement, cosmetics and medical device sectors. The company investigates the effects of substances, mixtures of active ingredients and surfaces on the human immune system in vitro under conditions that closely resemble those in vivo.

Based in Reutlingen, HOT Screen GmbH was established in 2014 through a management buyout of the former EDI GmbH, which had been acquired by the US company Rules Based Medicine, Inc. in October 2007. As before, its services include contract research in immunopharmacology, immunotoxicology and cell biology, as well as the custom development and validation of tailored cell culture systems and various types of immunoassays.

A key focus of its pharmacological testing services is substance screening and the profiling (characterisation) of active substances using a platform of human organotypic cultures (HOT Screening and HOT Profiling). These include whole-blood cultures and co-cultures combining immune cells with differentiated intestinal epithelia, epidermis, bronchial epithelium and other tissues. These systems make it possible to obtain an exceptionally comprehensive picture of the primary and secondary effects of active substances at the in vitro stage. This enables the targeted selection, from a range of comparable leads or drug candidates, of those active compounds with the most favourable activity profiles and the lowest likelihood of unwanted side effects for further development or clinical testing.

For use in clinical trials, HOT Screen GmbH has also developed a patented method (TruCulture®; distributed by IQVIA Laboratories Protein Biomarkers, USA) that enables functional testing of the human immune system at minimal cost, with previously unattained reliability and sensitivity.

Depending on their objectives, the cell-based assays performed by HOT Screen GmbH can be designed as pharmacological, toxicological or tolerability studies.

Category Services
Working areas Biomaterials, Life Science, Services, Research, Medical products
Year of foundation
1996 (EDI GmbH), 2014: HOT Screen GmbH
Employees
> 20